Status:
COMPLETED
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
Lead Sponsor:
Nathan Kline Institute for Psychiatric Research
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Schizophrenia
Diabetes
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The primary objective of the study is to assess whether chronic treatment with olanzapine over a five-month period produces a significant increase in abnormalities in glucose levels. The main secondar...
Detailed Description
In the on-going study in progress we use an extensive battery of assessments to investigate a)fasting levels of glucose and lipids at baseline and monthly during 5 months of treatment, b) glucose tole...
Eligibility Criteria
Inclusion
- Diagnosis
- Schizophrenia or schizoaffective psychosis
- 18-65 years of age
Exclusion
- Currently being treated with oral antidiabetics or insulin
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00287820
Start Date
February 1 2004
End Date
September 1 2007
Last Update
July 25 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manhattan Psychaitric Center
New York, New York, United States, 10035